Recursion Pharmaceuticals Inc. stocks have been trading up by 8.78 percent following upbeat news on its AI-driven drug discovery progress.
Click Here for a Millionaire's POV on Trading RXRX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- A Form 4 filing disclosed changes in beneficial ownership of Recursion Pharmaceuticals (RXRX) securities by an insider on 2026/09/16, extending a run of recent insider activity.
- A separate 2026/09/02 Form 4 also reported a change in insider ownership at RXRX, but without revealing who traded, the size, or whether it was a buy or sell.
- Another Form 4 dated 2026/09/10 recorded changes in insider beneficial ownership of RXRX securities, again without clarifying if it was a purchase, sale, or equity award.
- RXRX price action remains range-bound near the low-$3s, suggesting traders are watching filings and cash burn more than reacting to any single disclosure.
Live Update At 12:35:30 EDT: On Thursday, September 17, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 8.78%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
RXRX sits in classic high-risk biotech territory: big cash balance, big losses, and a stock grinding in a tight range. Over the past few weeks, Recursion Pharmaceuticals has mostly chopped between roughly $3.20 and $3.60, with the latest close near $3.46 after a modest push off recent lows around $3.16–$3.20. For short-term traders, RXRX has been a scalper’s market, not a clean trend.
The fundamentals explain why the stock is stuck. RXRX posted about $74.3M in revenue over the trailing period, but the key margins are deeply negative. EBITDA came in around -$112.5M for the latest reported quarter, and net income was about -$131M, translating to a loss of roughly $0.25 per share. Profitability ratios are brutal, with profit margins running in the negative hundreds of percent.
More Breaking News
- WULF Stock Rallies As AI Power Deals Transform Outlook
- GNRC Stock Soars As Amazon Data Center Deal Reprices Growth
- Nokia Stock Jumps As AI, Defense Deals Drive Rerating
- MARA Stock Pops As Wall Street Backs AI Data Center Pivot
At the same time, RXRX is not running on fumes. The balance sheet shows around $545.7M in cash and short-term investments and a current ratio near 5, with very low debt relative to equity. That gives Recursion Pharmaceuticals time, but not a free pass. Traders watching RXRX need to balance that cash runway against the company’s heavy burn and rich price-to-sales ratio above 30.
Why Traders Are Watching RXRX Insider Filings
The real storyline around RXRX this month is not a splashy partnership or a surprise earnings beat. It’s a drumbeat of insider Form 4 filings, all short on detail, but frequent enough to get the trading crowd’s attention.
On 2026/09/16, a Form 4 reported a change in beneficial ownership of Recursion Pharmaceuticals securities by an insider. Earlier, a 2026/09/02 filing showed another insider beneficial ownership change in RXRX, again without disclosing who traded, how large the move was, or whether it was a buy or a sell. In between, a 2026/09/10 Form 4 logged yet another change in insider beneficial ownership of RXRX securities, without stating if it was a purchase, sale, or equity award.
For active traders, Form 4s are like footprints in fresh snow. They show someone on the inside is moving, but not always where they’re heading. With RXRX, the pattern is clear: multiple insider ownership changes over a short stretch of September, but zero color on direction or size. That makes these filings a “monitor, don’t chase” catalyst.
Layer that on top of the chart. RXRX has shown controlled intraday volatility, opening around $3.28 and pushing to highs near $3.59 before closing just under $3.47. Midday trading shows a slow grind up from the $3.20s into the mid-$3.50s, then a fade. That’s classic day-trader territory — enough range to trade, but no conviction breakout yet. The insider activity gives traders one more reason to keep RXRX on the screen, even if it doesn’t provide a clear bullish or bearish read.
Conclusion
RXRX is a textbook example of a speculative biotech that still has time on the clock but not much room for sloppy execution. Recursion Pharmaceuticals is burning over $100M in free cash flow in a quarter, yet it’s backed by more than half a billion dollars in cash and a light debt load. That combination explains why RXRX is not collapsing, but also why traders are unwilling to pay up aggressively.
The recent streak of Form 4 filings — on 2026/09/02, 2026/09/10, and 2026/09/16 — confirms that insiders at RXRX are active, but those disclosures stop short of telling traders whether insiders are leaning bullish or hedging their exposure. With no information on direction, size, or type of transaction, these filings are signals to watch, not green lights to follow.
For day and swing traders, the plan with RXRX is mostly technical and disciplined. Respect the range, recognize the heavy losses, and remember that high price-to-sales names can re-rate fast if sentiment turns. As Tim Bohen, lead trainer with StocksToTrade says, “A consistent trading routine beats sporadic action every time. Show up daily, and you’ll start to see the patterns others miss.” As Tim Sykes often says, “Patterns repeat, but only traders who cut losses quickly and don’t fall in love with a story live to trade the next one.” RXRX gives plenty of volatility and headlines; the key is treating both as data, not destiny.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.